NCT07068529Toboroz
Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-CRC
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. júl. 16. · Több mint 12 hónapja nem frissült - kérdezd meg a helyszínt, nyitott-e még
Rövid összefoglaló (regiszter, angolul)
This prospective clinical observational study aims to construct a metabolite database specifically for colorectal cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in colorectal cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.
- Állapot (regiszter)
- Toboroz
- Vizsgálattípus
- Megfigyeléses
- Résztvevők száma
- 250 (tervezett)
- Első benyújtás
- 2025. júl. 7.
- Kezdés
- 2025. jún. 15.
- Elsődleges befejezés
- 2028. júl. 1.
- Fő szponzor
- Shanghai Minimally Invasive Surgery Center
- Betegségek
- Vastagbélrák
- NCT-szám
- NCT07068529
Mit vállalsz
- Vizsgálat típusa: Megfigyeléses
- Tervezett résztvevők: 250
- 2025. jún. 15. és az elsődleges befejezés (2028. júl. 1.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Currently participating in an interventional clinical study or receiving study treatment that may influence the patient's treatment decision;
- Long-term use of medications that may affect metabolism, such as hormones, immunosuppressants, antibiotics, etc.;
Más betegség
- \*\*Healthy Controls:\*\*
- Individuals at high risk for hereditary colorectal adenocarcinoma, including family members of the following diseases: family history of gastrointestinal tumors, familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC/LS), and Peutz-Jeghers syndrome (P-J syndrome);
- History of chronic metabolic or inflammatory diseases that are difficult to control, such as hypertension, diabetes, chronic viral hepatitis, and inflammatory bowel disease;
- Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured;
- History of oral or intravenous use of broad-spectrum antibiotics and probiotics within the past month;
- Regular use of immunosuppressive drugs within the past 6 months;
- Long-term use of other medications that may affect metabolism, such as hormones;
- Inability or unwillingness to cooperate with follow-up visits and related examinations;
- Inability to eat normally or requiring medications or enemas for bowel movements;
- Presence of psychiatric disorders or other severe cardiovascular diseases;
- Pregnant, breastfeeding, or planning to become pregnant within the next year;
- Currently participating in an interventional clinical study or receiving study treatment that may influence the patient's treatment decision.
- \*\*Colorectal Cancer:\*\*
- A clear family history of hereditary colorectal cancer, such as Lynch syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, etc.;
- Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured;
- History of chronic metabolic or inflammatory diseases that are difficult to control, such as hypertension, diabetes, chronic viral hepatitis, and inflammatory bowel disease;
- Presence of psychiatric disorders or other severe cardiovascular diseases;
- Any severe and/or uncontrolled medical conditions, as judged by the investigator, that may affect the patient's ability to participate in the study or interfere with study results.
Egyéb
- Presence of poorly controlled chronic comorbidities that may affect prognosis;
- Pregnant, breastfeeding, or planning to become pregnant within the next year;
Kiket keres a vizsgálat
- \*\*Healthy Controls:\*\*
- Age ≥ 18 years;
- Signed informed consent and willingness to participate in the project.
- \*\*Colorectal Cancer:\*\*
- Age ≥ 18 years;
- Performance status (ECOG) score ≤ 1;
- Histopathologically confirmed colorectal adenocarcinoma;
- No family history of hereditary cancer;
- No prior anti-tumor treatment;
- Availability of primary tumor tissue from surgery or biopsy that meets submission requirements;
- Availability of peripheral blood samples that meet submission requirements;
- Willingness and ability to sign the informed consent form to participate in the study.
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Ruijin Hospital Shanghai Jiaotong University School of Medicine Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát | Shanghai | Kína | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.